Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Protagonist Therapeutics Inc.

www.protagonist-inc.com

Latest From Protagonist Therapeutics Inc.

Deals Shaping The Medical Industry, June 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.

Deals BioPharmaceutical

Deal Watch: Array Partners With Ono On Cancer Drugs In Japan, South Korea

French biotechs Servier and ILTOO sign an option agreement for the latter's IL-2 inhibitor for lupus, while Korean biotechs LegoChem and Bridge will team up in idiopathic pulmonary fibrosis.

Deals Business Strategies

Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor

J&J's Janssen committed up to $990m plus royalties to collaborate with peptide drug developer Protagonist on an oral IL-23 inhibitor for Crohn's disease, which hits a similar target as two key assets in J&J's immunology portfolio: Stelara and the Phase III biologic guselkumab.

Deals Business Strategies

Pipeline Watch: Phase III Starts With Durvalumab, Atezolimumab And Eravacycline

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Inflammation
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Protagonist Therapeutics Inc.
  • Senior Management
  • Dinesh V Patel, PhD, Pres. & CEO
    Thomas P O'Neil, CFO
    David Y Liu, PhD, CSO & Head, R&D
    William A Hodder, SVP, Corp. Dev.
  • Contact Info
  • Protagonist Therapeutics Inc.
    Phone: (510) 474-0170
    7707 Gateway Blvd., Ste. 140
    Newark, CA 94560-1160
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register